Suarez-Almazor M E, Tao S, Moustarah F, Russell A S, Maksymowych W
Rheumatic Disease Unit, University of Alberta, Edmonton, Canada.
J Rheumatol. 1995 Nov;22(11):2027-33.
To determine the relationship of DR1, DR4, and DR4 subtypes with disease severity in patients with rheumatoid arthritis (RA).
We studied a cohort of 103 Caucasian patients with an onset of disease in 1985, and 6 to 7 years of disease at the time of the study. All rheumatologists in Edmonton participated in the city wide study which included hospital and community based patients with mild and severe disease. HLA status was determined using polymerase chain reaction amplification and amplified fragment length polymorphism typing. Outcome measures included joint counts, radiological scores, and physical functional status.
Fifty-six patients (54%) were DR4 positive, (OR = 2.3, 95% CI 1.4-3.6, compared to controls). This association was only statistically significant for seropositive patients (OR = 2.8 in seropositive patients and OR = 1.5 in seronegative patients). A higher risk was observed for DR1/DR4 heterozygotes (OR = 6.8 in seropositive patients and OR = 1.7 in seronegative patients). No significant differences were observed in disease activity, joint counts, radiological scores, or functional status among patients carrying 1, 2 or no disease related alleles, although the prevalence of rheumatoid factor (RF) showed a linear association with allele dose (0, 1, or 2).
DR4 and in particular DR1/DR4 heterozygosity were related to susceptibility to RA only in seropositive patients. RF was a better predictor of severity than disease related HLA subtypes. These findings suggest that the effect of these alleles on severity may be related to seropositivity, or that perhaps, seropositive and seronegative RA are genetically distinct entities. The results of our study suggest that in community based settings, which include patients with milder disease, DR1 and DR4 disease related alleles increase susceptibility for RA, but are not clinically useful as predictors of longer term outcome.
确定DR1、DR4及DR4亚型与类风湿关节炎(RA)患者疾病严重程度之间的关系。
我们研究了一组1985年发病、在研究时患病6至7年的103名白种人患者。埃德蒙顿的所有风湿病学家都参与了这项全市范围的研究,该研究纳入了来自医院和社区的病情轻重不一的患者。使用聚合酶链反应扩增和扩增片段长度多态性分型来确定HLA状态。结果指标包括关节计数、放射学评分和身体功能状态。
56名患者(54%)为DR4阳性(与对照组相比,OR = 2.3,95%CI 1.4 - 3.6)。这种关联仅在血清阳性患者中具有统计学意义(血清阳性患者中OR = 2.8,血清阴性患者中OR = 1.5)。DR1/DR4杂合子的风险更高(血清阳性患者中OR = 6.8,血清阴性患者中OR = 1.7)。在携带1个、2个或无疾病相关等位基因的患者中,疾病活动度、关节计数、放射学评分或功能状态未观察到显著差异,尽管类风湿因子(RF)的患病率与等位基因剂量(0、1或2)呈线性关联。
DR4,尤其是DR1/DR4杂合性仅在血清阳性患者中与RA易感性相关。RF比疾病相关的HLA亚型更能预测疾病严重程度。这些发现表明这些等位基因对严重程度的影响可能与血清阳性有关,或者也许血清阳性和血清阴性RA是基因上不同的实体。我们的研究结果表明,在包括病情较轻患者的社区环境中,DR1和DR4疾病相关等位基因会增加RA易感性,但作为长期预后的预测指标在临床上并无用处。